Please ensure Javascript is enabled for purposes of website accessibility

Novavax Coronavirus Vaccine Candidate Shows 96% Efficacy With Original Strain, 86% Against U.K. Variant

By Eric Volkman - Updated Mar 11, 2021 at 9:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The efficacy was far lower against the South African variant, though.

Will Novavax's (NVAX -8.57%) NVX-CoV2373 be the next coronavirus vaccine to win major regulatory approval? Its prospects look good after the company's release of two sets of clinical trial data on Thursday.

The first, drawn from a phase 3 study in the U.K., indicate that the vaccine candidate was 96.4% efficacious against mild, moderate, and severe COVID-19 caused by the original strain of the coronavirus. Against the so-called "U.K. variant," which is apparently far more transmissible, NVX-CoV2373's efficacy was 86.3%.

The second is from a phase 2b clinical trial that took place in South Africa, where the "South African" variant of the coronavirus is rampant. The vaccine was found to be 55.4% efficacious in HIV-negative participants receiving inoculation.

Child getting a jab from a medical professional.

Image source: Getty Images.

Novavax added that, in both studies, NVX-CoV2373 demonstrated 100% protection against severe COVID-19 and prevented all hospitalization and death. The vaccine was well-tolerated and produced low levels of severe, serious, and medically attended adverse events.

The news comes as those variants continue to spread in certain geographies. Also, while vaccine rollout in many countries is gathering pace, complete inoculations are still in the single digits in many nations. One of these is the U.S., which, according to data compiled by The New York Times, hasn't quite reached 10% of the population yet.

While anxious observers might be concerned that the efficacy of the Novavax vaccine against the South African variant could be higher, it's still good by traditional vaccine measures at over 55% efficacy. As such, assuming it's approved by major regulators like the U.S. Food and Drug Administration, it should be an effective new weapon in the fight against the coronavirus.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$53.42 (-8.57%) $-5.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.